Klinische Studie

REFINE-CAC Protocol: Risk Evaluation With AI-CPA + HCS For Patients IN Whom Calcium is confirmEd to Improve Coronary Artery Disease Care

NCT: NCT07853716 · NOT_YET_RECRUITING

NCT-IDNCT07853716

Medizinische Daten: StatusNOT_YET_RECRUITING

SponsorHeartFlow, Inc. (INDUSTRY)

First posted2026-10-02

Last updated2026-10-02

Kurzzusammenfassung

REFINE-CAC is a prospective, multi-center trial assessing the management of asymptomatic participants with CAC scores 1-299 Agatston units or incidental CAC findings on chest computed tomography (CT), all of whom will undergo CCTA and are blinded to the coronary anatomy (e.g., % stenosis). The trial includes a randomized, controlled pathway and a single arm, observational registry pathway.

Offizielle Quelle

Auf ClinicalTrials.gov ansehen →

Daten aus der ClinicalTrials.gov-API. Den aktuellsten Status finden Sie im offiziellen Eintrag.